Phase II trial of combination bevacizumab and temsirolimus in the treatment of recurrent or persistent endometrial carcinoma: a Gynecologic Oncology Group study.

MLA

Alvarez, Edwin A., et al. “Phase II Trial of Combination Bevacizumab and Temsirolimus in the Treatment of Recurrent or Persistent Endometrial Carcinoma: A Gynecologic Oncology Group Study.” Gynecologic Oncology, vol. 129, no. 1, Apr. 2013, pp. 22–27. EBSCOhost, https://doi.org/10.1016/j.ygyno.2012.12.022.

APA

Alvarez, E. A., Brady, W. E., Walker, J. L., Rotmensch, J., Zhou, X. C., Kendrick, J. E., Yamada, S. D., Schilder, J. M., Cohn, D. E., Harrison, C. R., Moore, K. N., & Aghajanian, C. (2013). Phase II trial of combination bevacizumab and temsirolimus in the treatment of recurrent or persistent endometrial carcinoma: a Gynecologic Oncology Group study. Gynecologic Oncology, 129(1), 22–27. https://doi.org/10.1016/j.ygyno.2012.12.022

Chicago

Alvarez, Edwin A, William E Brady, Joan L Walker, Jacob Rotmensch, Xun C Zhou, James E Kendrick, S Diane Yamada, et al. 2013. “Phase II Trial of Combination Bevacizumab and Temsirolimus in the Treatment of Recurrent or Persistent Endometrial Carcinoma: A Gynecologic Oncology Group Study.” Gynecologic Oncology 129 (1): 22–27. doi:10.1016/j.ygyno.2012.12.022.